Pharmaceutical manufacturer Aurobindo Pharma on Friday said it posted a standalone net profit of Rs.340.09 crore for the second quarter of 2015-16 against a net profit of Rs.391.66 crore in the same period last year, showing a 13.16 percent dip.
According to the statement of standalone unaudited results posted on the Bombay Stock Exchange (BSE), the company's total income from operations rose to Rs.2,175.93 crore from Rs.2,007.70 crore while total expenditure increased to Rs.1,690.50 crore from Rs.1,468.66 crore.
On consolidated basis, Aurobindo Pharma posted a net profit of Rs.451.76 crore in Q2 against Rs.372.18 crore in the last quarter, while total income from operations rose to Rs.3,333.43 crore from Rs.2,881.22 crore.
Aurobindo Pharma incurred a total expenditure of Rs.2,650.65 crore in the reviewed quarter on a consolidated basis against Rs.2,333.86 crore in the previous quarter.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
